Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00513994 · ClinicalTrials.gov registry record · Phase 1
MQX-503 vs Nitroglycerin Ointment: A Pharmacokinetic Comparison in Normal Subjects
A Phase 1 study, sponsored by MediQuest Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT00513994: Completed Phase 1 study, sponsored by MediQuest Therapeutics.
NCT00513994 is a Phase 1 study that has completed, run by MediQuest Therapeutics. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00513994, a Phase 1 study, has completed, sponsored by MediQuest Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of the study is to measure how much nitroglycerin or its metabolites may be found in the bloodstream when MQX-503 or an FDA approved Nitroglycerin ointment 2% USP is applied to the skin of healthy subjects.
Interventions
- DRUG Nitroglycerin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2007-08 |
| Est. Completion | 2007-10 |
| Phase | Phase 1 |
What the finished NCT00513994 record still lists
NCT00513994 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which Nitroglycerin is the first listed.
NCT00513994 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00513994 about?
NCT00513994 is a clinical study titled "MQX-503 vs Nitroglycerin Ointment: A Pharmacokinetic Comparison in Normal Subjects". The purpose of the study is to measure how much nitroglycerin or its metabolites may be found in the bloodstream when MQX-503 or an FDA approved Nitroglycerin ointment 2% USP is applied to the skin of healthy subjects.
What is the current status of trial NCT00513994?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2007-08. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00513994?
The interventions under investigation include: Nitroglycerin (DRUG).
Who is sponsoring clinical trial NCT00513994?
This trial is sponsored by MediQuest Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00513994's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia